Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 4/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 2/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 2/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.69 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154047 | 0.94 | TGFBR1 (0.89) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4084904 | 0.91 | TGFBR1 (0.84) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL28825919 | 0.89 | TGFBR1 (0.82) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7590309 | 0.88 | TGFBR1 (0.78) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6181382 | 0.88 | TGFBR1 (0.78) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5139175 | 0.86 | TGFBR1 (0.79) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13998757 | 0.85 | TGFBR1 (0.75) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4085338 | 0.85 | TGFBR1 (0.74) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5503286 | 0.85 | TGFBR1 (0.74) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13998763 | 0.85 | TGFBR1 (0.73) | TGFBR1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099237-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | claimed |
| WO-2009047163-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | claimed |
| US-20080146617-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | claimed |
| WO-2008071605-A2 | METHODS OF TREATING INFLAMMATORY DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | WO | claimed |
| EP-1771171-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | Schering-Plough Ltd. (CH) | 2007-04-11 | — | — | EP | claimed |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | SCHERING CORPORATION | 2006-08-31 | — | — | US | claimed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | claimed |
| EP-1169317-B1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| JP-2002541253-A | — | — | 2002-12-03 | — | — | JP | claimed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | claimed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | claimed |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-11987558-B1 | ALK5 inhibitors and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-1169317-B1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | disclosed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885MAPK13 1936/4885 |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | ALK, ACVR1, MSTN | TGFBR1 56/4885MAPK14 1382/4885MAPK13 1750/4885 |
| US-11987558-B1 | ALK5 inhibitors and their uses | ALK, ALKBH3, ALKBH5 | TGFBR1 106/4885MAPK14 1923/4885MAPK13 1165/4885 |
| US-20090099237-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | TGFBR1 3096/4885MAPK14 718/4885MAPK13 793/4885 |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, CD2, TGFBR2 | TGFBR1 5/4885MAPK14 1007/4885MAPK13 1169/4885 |
| US-20080146617-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | TGFBR1 3096/4885MAPK14 718/4885MAPK13 793/4885 |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885MAPK13 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.